As communicated through a press release on March 11, 2025, the board of directors of PEPTONIC Medical AB (publ) (the “Company”) decided to submit an
As part of its growth strategy in the US market, Peptonic Medical AB (publ) (“Peptonic” or the “Company”) has established a new wholly-owned subsidiary, Peptonic
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the press release issued on March 14, 2025, titled “Court of Appeal convicts former employees
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the Court of Appeal has overturned the District Court’s acquittal in the insider trading case
Peptonic Medical AB (publ.) (“Peptonic” or “the Company”) announces that the Uppsala District Court has approved the Company’s application for corporate restructuring. This decision enables
The Board of Directors of Peptonic Medical AB (publ.) (“Peptonic” or “the Company”) has today decided to submit an application for corporate restructuring. This decision
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) is adjusting its organization following the structural changes implemented in 2024. As part of this process, the
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (publ) (“Peptonic” or “the Company”) is thrilled to announce the highly anticipated U.S. launch of its portfolio of intimate care products under
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical (publ) (“Peptonic” or “the Company”) has had a highly successful launch of VagiVital Intimate Calming Gel in Sweden, with nearly 1,000 units sold
Peptonic Medical (publ) (“Peptonic” or “the Company”) announces the launch of VagiVital Intimate Calming Gel, a specially developed product that provides immediate moisture while relieving
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (publ) (“Peptonic” or “the Company”) announces the successful launch of its in-house developed lubricant, VagiVital Active Glide, at the turn of the
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announces that the United States Patent and Trademark Office (“USPTO”) has granted a patent for the relief
The extraordinary general meeting of PEPTONIC medical AB, reg. no. 556776-3064 (the “Company”), was held today on 7 January 2025. The meeting resolved, with the
N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the extraordinary general meeting in PEPTONIC medical AB,
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic Medical AB (publ) (“Peptonic”) is taking a crucial step to establish its VagiVital brand in the U.S. market and drive sales growth of its
Peptonic Medical (publ) today announced that Apotek Hjärtat is initiating sales of the company’s leading intimate care product VagiVital® AktivGel in most of its physical
Peptonic Medical (publ) today informed the company has signed an exclusive distributor agreement for Central Amerika with Windsor Pharmaceutical concerning the companys vaginal self tests
Peptonic Medical (publ) (‘Peptonic’ or ‘the Company’) informs that the company has entered into an agreement with fermata Inc. for the Japan market. The agreement
Peptonic Medical AB (publ) (“Peptonic” or “the Company”) announces today that it has decided to exercise the right to convert the loan of SEK 7.5
www.aktietorget.se ticker: PMED 2019 third quarter (Jul-Sep) Net sales of products KSEK 1,557 (120) Gross profit KSEK 692 (95), Gross margin 45% (79%) Operating loss
2019 first quarter (Apr-Jun) Net sales of products KSEK 1,011 (0) Gross profit KSEK 768 (0), Gross margin 76% (0%) Operating loss KSEK -5,102 (-3,563)
The Board of Directors of Peptonic Medical AB (publ) (Peptonic or Company) today announced the decision to commence the process of obtaining CE-marking for the
Peptonic Medical AB (publ) today announced that the primary efficacy endpoints of the first part of its phase 2b study, in which the Vagitocin® gel
Peptonic Medical AB (publ) (“the Company” or “Peptonic”) – a company developing pharmaceuticals based on oxytocin – today announced that 57 study subjects have been
PEPTONIC medical (publ) today announced it has engaged five study sites, all of them in Sweden, to participate in the next Phase 2b study and
PEPTONIC medical today announced the tentative program for company presentations during the subscription period for the rights issue in connection with the planned listing (IPO)
PEPTONIC medical today announces that, at the PEPTONIC medical Annual General Meeting on April 8th, Mrs Nadia Whittley was elected as a new member to
PEPTONIC medical (publ) today announced that the Annual General Meeting (AGM) on April 8th resolved to make the Company to a public company. In conjunction
PEPTONIC medical today announced that it has recruited Johan Inborr to lead the business development activities of the company on a consultancy basis. Johan is
PEPTONIC medical today announced that it has raised SEK 6.9 million in a directed private placement to existing and new shareholders. After the private placement,
PEPTONIC medical today announced that it has completed the evaluation of different tube models and materials for use as primary packaging of VAGITOCIN® – the
PEPTONIC medical today announced that the last patient participating in the VAGITOCIN® pharmacokinetic (PK) study has been discharged after a final visit to the physician
PEPTONIC medical today announced that it met with the US Food and Drug Administration (FDA) earlier this month in a so called pre-IND meeting. The
PEPONIC medical has signed an agreement with Destum Partners in USA for support in finding suitable collaboration partners. By using a US based consulting company
PEPTONIC has started a collaboration with Clinartis in USA. Clinartis is a consulting company within the clinical/regulatory area. They support us in the work with
A regulatory/scientific, advisory meeting has been performed at the MPA on the 25.3.13. The results from the recently concluded clinical study and the design of
A new formulation patent for oxytocin was approved by the Swedish patent authorities in February 2013. PEPTONIC has received a patent on the new formulation
PEPTONIC medical has concluded a preference share emission which gave 13,6 MSEK. During October 2012 a preference share emission was finished giving 13,6 MSEK. This
